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Tuesday, February 5, 2013 445aRyR1 and its protein ligands are often not stable in vitro and therefore difficult
to study by single-particle cryo-electron microscopy (cryo-EM). The main goal
of this study was to develop a procedure to cross-link protein ligands to RyR1
and visualize these complexes by single-particle cryo-EM. To test the cross-
linking protocol we used the complex of FK506-binding protein and RyR1
(FKBP12:RyR1) as a model system, since the structure of FKBP12:RyR1 is
known. Glutaraldehyde quantitatively cross-linked RyR1 subunits to each other
and FKBP12 to RyR1 without damaging the ultrastructure. Cross-linked
FKBP12:RyR1 was visualized in 2D averages, and was identical to that of pre-
viously published non-cross-linked FKBP12:RyR1. The effect of glutaralde-
hyde cross-linking on RyR1 structure was characterized using 3D single-
particle cryo-EM and by [3H]ryanodine binding assay. Glutaraldehyde cross-
linking preserved the gross morphology of RyR1, but induced minor structural
changes at the cytoplasmic and transmembrane regions of RyR1. Glutaralde-
hyde cross-linking enhanced [3H]ryanodine binding to RyR1 by ~30%. Based
on these results we propose that cross-linking RyR1 subunits by glutaraldehyde
locked RyR1 in an open-like conformation state.
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The type 1 ryanodine receptor (RyR1) is an intracellular Ca2þ release channel
that mediates skeletal muscle excitation contraction coupling. While the over-
all shape of RyR1 has been elucidated using cryo electron microscopic recon-
structions, fine structural details remain elusive. To better understand the
structure of RyR1, we have previously used a fluorescence resonance energy
transfer (FRET)-based method using a fused green fluorescent protein (GFP)
donor and a fluorescent acceptor, Cy3NTA that binds specifically to short
poly-histidine ‘tags’ engineered into RyR1. However, the large size of the
GFP fusions and the need to permeabilize cells expressing these constructs
(to allow Cy3NTA entry) limits interpretation of the resulting FRET data.
To overcome these problems, we used a dodecapeptide sequence containing
a tetracysteine (Tc) motif to target the bi-arsenical fluorophores, FlAsH and
ReAsH to RyR1. These compounds freely cross intact cell membranes where
they then bind covalently to the tetracysteine motif. First, we used this system
to conduct FRET measurements in intact cells by fusing a YFP FRET donor
to the N-terminus of RyR1 and then targeting the FRET acceptor, ReAsH to
an adjacent Tc tag. High levels of energy transfer (~50%) were observed
whereas incubation of ReAsH with a YFP-RyR1 fusion protein lacking the
Tc tag resulted in no detectable FRET. We also developed a FRET-based
system that did not require GFP fusions into RyR1 by labeling N-terminal
Tc-tagged RyR1 with FlAsH, a FRET donor and then targeting the FRET
acceptor Cy3NTA to an adjacent His tag. A high degree of energy transfer
(~70%) indicated proper binding of both compounds to these unique recogni-
tion sequences in RyR1. Thus, these two systems provide unprecedented flex-
ibility in FRET-based structural determinations of RyR1. Supported by NIH
grant R01AR059124.
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We used fluorescence resonance energy transfer (FRET) to localize three
divergent region domains within the type 1 ryanodine receptor (RyR1), an in-
tracellular Ca2þ channel that mediates skeletal muscle excitation-contraction
(EC) coupling. Initial cloning studies of the three RyR isoforms identified
three ‘‘divergent regions’’ of primary sequence dissimilarity spanning amino
acids 4254-4631 (DR1), 1342-1403 (DR2) and 1872-1923 (DR3) in RyR1.
These regions have been implicated in EC coupling as well as in differential
sensitivity to pharmacological agonists. Here, we used permeabilized HEK-
293T cells expressing recombinant RyR1 to localize these DRs to the cryo
electron microscopic (EM) map of RyR1. First, we measured FRET from
a green fluorescent protein (GFP) donor fused to either position 1 or 620 of
RyR1, to a FRET acceptor, Cy3NTA, targeted to poly-histidine ‘‘tags’’ in-
serted into DR1 (at position 4429), DR2 (at position1358) or DR3 (at position
1915). While FRET was not detected for His-tagged constructs containing
GFP fused at position 1, FRET was observed from GFP fused at position
620 to all 3 His-tagged positions. Second, we targeted a donor to the RyR1
cytoplasmic domain using FKBP12.6 labeled with Alexa Fluor 488, and
then measured FRET to Cy3NTA targeted to the His tag sites describedabove. Donor-FKBPs bound with high-affinity to both recombinant wild
type and His-tagged RyRs. FRET was detected from donor conjugated to
each of four, well-separated positions on FKBP to Cy3NTA targeted to
each divergent region. Since the fused GFPs and FKBP12.6 have already
been localized within the cryo EM map of RyR1, we can now triangulate
the DR positions to the cryo EM map from these two complementary data
sets. Supported by NIH grant R01AR059124 (to JDF, MM, and TG) and
R01HL092097 (to RLC).
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The skeletal muscle Ryanodine Receptor (RyR1) is a large calcium release
channel involved in excitation-contraction coupling. It is also the target for
hundreds of disease mutations that cause malignant hyperthermia (MH) or
skeletal muscle disorders like central core disease (CCD). MH is typically
triggered by volatile anesthetics, but their binding site on RyR1 has not
been fully described. RyR1 is under the control of several auxiliary proteins.
One of these is Calmodulin (CaM), a Ca2þ-binding protein that can suppress
RyR1 activity at elevated Ca2þ concentrations. Here we investigate how
CaM can bind to RyR1, and how this may be affected by volatile anesthetics.
We found that CaM can bind to at least three different RyR1 peptides, with
the affinity and lobe specificity being altered substantially by the Ca2þ
concentrations. In addition, we identified two binding sites for sevoflurane,
a volatile anesthetic, on Ca2þ/CaM. The anesthetic binds to a pocket that is
involved in binding RyR1 peptides. In addition, it can alter the affinity of
the N-terminal CaM lobe for Ca2þ. These findings suggest that binding of
anesthetics to CaM may be involved in the pathophysiology of malignant
hyperthermia.
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In skeletal muscle, RyR1 (5,037 residues) forms a homo-tetrameric Ca2þ-re-
lease channel in the sarcoplasmic reticulum (SR), mediates excitation-
contraction coupling in response to an orthograde signal from the DHPR in
the plasma membrane, and retrogradely enhances L-type Ca2þ current via
the DHPR. The RyR1 C-terminus forms the Ca2þ channel pore across the
SR membrane and is believed to be important for inter-subunit interactions,
whereas the bulk (~85%) of the protein (the so-called foot) bridges the junc-
tional, myoplasmic gap between the SR and plasma membranes. Here, we
have examined the ability of the foot domain (residues 1-4300; RyR11:4300)
to target junctionally and interact with the DHPR by expression of a cDNA en-
coding YFP-RyR11:4300. In dysgenic (a1S-null) myotubes which lack DHPRs,
YFP-RyR11:4300 was diffusely distributed and, on the basis of photobleaching,
freely mobile within the cytoplasm, consistent with the loss of membrane an-
choring. However, after expression in dyspedic (RyR1 null) myotubes (which
have DHPRs), much of YFP-RyR11:4300 was immobile within fluorescent foci
near the myotube surface, suggestive of junctional targeting and binding to
DHPRs. Junctional targeting was confirmed by partial co-localization of
YFP-RyR11:4300 and CFP-labeled a1S after co-expression in dyspedic myo-
tubes. Strikingly, YFP-RyR11:4300 was able to retrogradely enhance peak
Ca2þ current in dyspedic myotubes from 1.6 pA/pF (control) to 6.7 pA/pF, sim-
ilar to that after expression of full-length RyR1 (7.4 pA/pF). Thus, the isolated,
cytoplasmic foot of RyR1 retains the ability to target junctionally and to inter-
act functionally with the DHPR.
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In skeletal muscle, the dihydropyridine receptor (DHPR) in the plasma mem-
brane engages in bi-directional interactions with the type 1 ryanodine receptor
(RyR1) in the sarcoplasmic reticulum (SR) such that an ‘‘orthograde’’ signal
from the DHPR triggers SR Ca2þ release via RyR1, and a retrograde signal
446a Tuesday, February 5, 2013from RyR1 enhances the L-type Ca2þ current via the DHPR. RyR1 (5,037
residues) assembles as a homotetramer in which the C-termini form the ion
conducting pore across the SR membrane, with the remainder of the protein
forming a ‘‘foot’’ structure which spans between the SR and plasma mem-
branes. In an accompanying abstract (Polster et al., this meeting) we showed
that a construct (YFP-RyR11:4300) which lacks the C-terminal residues was
diffusely distributed in dysgenic myotubes (DHPR null), but that in dyspedic
myotubes (RyR1-null but containing DHPRs) it targeted junctionally and
retrogradely enhanced L-type Ca2þ current. Here we have examined the oligor-
merization of YFP-RyR11:4300. Measurement of FRAP for YFP-RyR11:4300 in
dysgenic myotubes yielded a diffusion coefficient of 2.17x108 cm2/sec,
which, based on previous measurements of protein diffusion in muscle, is
compatible with YFP-RyR11:4300 existing as a tetramer. We also used SDS
PAGE (4-15% gradient) and immunoblotting to compare YFP-RyR11:4300
(expressed in tsA-201 cells) and native RyR1. Without prior cross-linking,
YFP-RyR11:4300 displayed a smaller apparent MW than wt RyR1; after glutar-
aldehyde cross-linking, both proteins migrated as single bands of much higher
apparent MW, with YFP-RyR11:4300 again displaying a slightly greater mobil-
ity, consistent with it’s being a tetramer.
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A RyR1 construct that lacks the channel forming C-terminal residues but in-
cludes the entire cytoplasmic foot region (YFP-RyR11:4300) forms a stable tet-
rameric structure (H. Bichraoui et al., abstract this meeting), colocalizes with
DHPRs at SR/plasmalemma junctions and retrogradely enhances peak DHPR
currents when expressed in dyspedic (RyR1 null) myotubes (A. Polster et al.,
abstract this meeting). We tested the interaction of the expressed RyR11:4300
with DHPRs in dyspedic myotubes by examining the DHPR disposition using
freeze-fracture. Normally DHPRs are targeted to junctional sites in the absence
of RyR, but their organization into tetrads and the arrangement of tetrads in
ordered arrays is strictly dependent on their link to arrays of tetrameric
RyRs. Thus the disposition of DHPRs in freeze-fracture images provides direct
information both on DHPR/RyR interaction and on the arrangement of RyRs.
In dyspedic cells DHPR clusters at peripheral couplings in a loose, completely
random arrangement. Cells expressing full-length RyR1 show more tightly
clustered DHPRs and the presence of complete (4 elements) and incomplete
(2-3 elements) tetrads that are aligned in an orthogonal array. Cells expressing
the truncated RyR11:4300 show small well identifiable DHPR foci with closely
spaced particles. Some but not all foci show clear grouping of DHPRs into
complete tetrads and/or tetrads composed of only three elements, but the tetrads
are not aligned into a orthogonal array. We conclude that similar to intact
RyR1, RyR11:4300 forms homo-tetramers which can link to DHPRs and orga-
nize them into tetrads, but that the cytoplasmic RyR1 foot differs from full-
length RyR1 in that it does not form orthogonal arrays. The related positioning
of RyR11:4300 and DHPRs is necessary for the retrograde interaction between
the two.
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Skeletal (RyR1) and cardiac muscle (RyR2) isoforms of ryanodine receptor
calcium channels are ~65 % homologous in amino acid sequences; however
they differ in their regulation by endogenous molecules and proteins. Both
RyR1 and RyR2 are inhibited by millimollar Ca2þ, but RyR2 affinity for
inhibitory Ca2þ is ~10 times lower than RyR1. Previous studies demonstrated
that C-terminus quarter of RyR has critical domain(s) for Ca2þ inactivation
(Du and MacLennan (1999) J. Biol. Chem.274, 26120; Nakai et al. (1999)
FEBS Lett.459, 154). We pursued these observations to obtain further insights
into RyR regulation by Ca2þ. We constructed and expressed 8 RyR1/RyR2
chimeras in HEK293 cells and determined Ca2þ activation and inactivation
affinities of these channels by [3H]ryanodine ligand binding method. We
found that replacing two regions of RyR1 with corresponding RyR2 sequence
reduced the affinity for Ca2þ inactivation. The first region (RyR2 amino acid
4020-4250) contains two EF hand Ca2þ binding motifs (EF1: 4036-4047,
EF2: 4071-4082). Another chimera containing only EF2 of RyR2 (RyR2
4053-4250) has only a modest (not significant) change in Ca2þ inactivation.The results suggest that EF1 is a critical determinant for RyR inactivation
by Ca2þ. Consistently, a chimera channel carrying only RyR2-EF1 (RyR2
3692-4052) showed significantly reduced Ca2þ inactivation, whereas a chi-
mera carrying RyR2 3692-4019 (no EF hands) behaved essentially as
RyR1. Second, preliminary studies indicate that substitution of the last
~450 amino acids of RyR1 with corresponding RyR2 (4521-4968) results in
Ca2þ inactivation affinity between RyR1 and RyR2. Replacing both regions
in RyR1 with RyR2 sequences (4020-4250 and 4521-4968) further reduced
Ca2þ inactivation affinity, which suggests that in addition to EF1, C-terminal
~450 amino acids have a role in Ca2þ-dependent inactivation of RyRs.
Supported by NIH, AHA and NSF.
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Using fluorescence resonance energy transfer (FRET), we are testing the hy-
pothesis that S100A1 competes with calmodulin (CaM) for binding to cardiac
ryanodine receptors (RyR2). In isolated pig cardiac sarcoplasmic reticulum
(SR) vesicles, we targeted a donor-labeled FKBP (D-FKBP) to the RyR2
cytosolic headpiece. We then detected FRET as a decrease of donor fluores-
cence in the presence of CaM labeled with acceptor within the N- or C-lobe
(denoted AN-CaM and AC-CaM, respectively), thus directly and specifically
indexing CaM binding in the proximity of D-FKBP. FRET between
D-FKBP and A-CaMs (100 nM) was completely inhibited by unlabeled
WT-CaM, with KIz 100 nM, indicating that WT-CaM and A-CaMs compete
with similar affinities for the same RyR2 binding site. However, S100A1
(ranging from 0.1 to 30 mM) had no significant effect on FRET when cardiac
SR was concurrently incubated with S100A1 and AN-CaM. Upon sequentially
incubating the SR with S100A1 first, then with AN-CaM, we found partial
inhibition of FRET, but with KI z 30 mM S100A1. This effect is more pro-
nounced in nM Ca2þ (versus mM Ca2þ). Intriguingly, FRET between D-FKBP
and AC-CaM was not significantly affected by S100A1. S100A1 lowered
maximum FRET for AN-CaM but did not significantly change its binding
affinity. This suggests that S100A1 allosterically interacts with RyR-CaM
binding, rather than directly competing for the same binding site as CaM.
We are currently developing a complementary FRET approach, using
acceptor-labeled S100A1, to specifically resolve the S100A1 binding to
RyR. Ultimately, we aim to elucidate the interplay between S100A1 and
CaM binding to RyR.
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We have reported that CGP-37157, a benzothiazepine (BZT) derivative of
clonazepam utilized as a blocker of the mitochondrial Naþ/Ca2þ exchanger,
also activates ryanodine receptors (RyRs) and inhibits the sarcoplasmic retic-
ulum (SR) Ca2þ-stimulated ATPase (SERCA). We extended the studies to
other BZT (e.g., clonazepan, diltiazem) as well as to benzodiazepines
(BZD; e.g. diazepan, lorazepan). We aimed to determine if these drug classes
have as a common trait the ability to modulate RyRs and/or SERCA. The
effects of BZD and BZT on RyRs activity were tested in SR microsomes
with a Ca2þ leak assay as well as after reconstituting RyRs into lipid bilayers.
The agents tested had variable potency to increase RyR-mediated Ca2þ leak
from skeletal SR microsomes. As an example, while diazepam significantly
increased RyR activity, most of the others (clonazepam, lorazepam) had
minor effects at high doses. In contrast, diltiazem produced moderate inhibi-
tion. Planar bilayer studies confirmed the leak observations with both cardiac
and skeletal RyR. In the presence of ruthenium red, most agents decreased
the rate of loading which indicates inhibitory effects on SERCA activity.
The effects of BZT and BZD on loading correlated with a decrease in
ATPase activity of SERCA-enriched skeletal SR fractions. In summary,
most BZT and BZD utilized in therapeutics or as pharmacological tools
have an inhibitory action on SERCA. In contrast, they show a variety of ef-
fects on RyRs ranging from inhibition to activation. Hence, the pharmacolog-
ical action of BZT and BZD on cellular Ca2þ homeostasis reported in the
literature of cardiac and skeletal muscle as well as other non-muscle systems
may require taking into consideration the contributions of all drug-sensitive
intracellular Ca2þ transporters. (Supported by NIH-GM078665 and AHA-
MWA 12180038).
